A Study of Continuous Infusions of HNO (Nitroxyl) Donor in Patients With Heart Failure and Impaired Systolic Function

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
visit www.BMSStudyConnect.com

Inclusion Criteria:

- Heart failure with reduced ejection fraction (LVEF on echocardiogram of 40% or less)

- Stable guideline directed therapy for heart failure including oral diuretics, ACEi,
ARBs, ARNi, MRAs, and β blockers as tolerated, with no dose changes of these
medications in the past 2 weeks

- Have screening values of NT pro-BNP ≥ 125 pg/mL (15 pmol/L) or BNP ≥ 35 pg/mL (10
pmol/L)

Exclusion Criteria:

- Systolic blood pressure (SBP) < 110 mm Hg at screening or pre-randomization

- Heart rate < 50 beats per minute (bpm) or > 90 bpm at screening or pre-randomization

- Permanent Atrial Fibrillation, Atrial Flutter or having Atrial Fibrillation, Atrial
Flutter

- Estimated glomerular filtration rate (eGFR) < 15 ml/min/1.73 m2

- Ventricular assist device or prior heart transplant

- Prior solid organ transplant

- Body weight < 45 kg or ≥ 140 kg

- Low quality echocardiographic visualization windows and image acquisition

- Permanent paced rhythm (VVI, DDD or BiV pacing)

Other protocol defined inclusion/exclusion criteria could apply